导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.89% | 1517/4773 |
| 近一周 | -0.70% | 1193/5465 |
| 近一月 | -2.82% | 1935/5421 |
| 近一季 | -7.13% | 2677/5231 |
| 近半年 | -4.32% | 2786/4920 |
| 近一年 | 8.86% | 1269/4394 |
| 近两年 | 66.51% | 1076/2954 |
| 近三年 | 29.71% | 1099/2253 |
| 成立以来 | 46.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.38% 951/4961 |
13.56% 1986/5312 |
- - |
- - |
| 2025 | 31.85% 1213/4813 |
2.27% 1417/3635 |
2.22% 1739/4076 |
24.81% 1434/4524 |
1.04% 1577/4813 |
| 2024 | -0.11% 2099/3463 |
-3.92% 1581/2808 |
-4.12% 1469/3014 |
11.15% 2548/3129 |
-2.45% 2087/3463 |
| 2023 | -7.35% 911/2656 |
6.90% 631/2280 |
-3.40% 790/2385 |
-5.62% 1347/2515 |
-4.93% 1215/2655 |
| 2022 | -23.42% 1134/2207 |
-13.00% 680/1919 |
1.76% 1426/2016 |
-12.64% 747/2113 |
-0.99% 1665/2208 |
| 2021 | 8.44% 478/1822 |
-6.56% 1018/1255 |
12.98% 299/1330 |
1.50% 448/1466 |
1.20% 987/1822 |
| 2020 | 38.52% 355/1250 |
-5.11% 400/1028 |
22.66% 200/1067 |
10.85% 504/1164 |
7.36% 715/1184 |
| 2019 | 27.39% 547/1092 |
25.53% 460/739 |
-8.90% 617/788 |
4.07% 221/850 |
7.04% 497/918 |
| 2018 | -30.88% 482/834 |
- - |
-13.85% 464/631 |
-6.43% 404/660 |
-10.90% 235/682 |
| 2017 | 10.91% 298/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 南方中证500量化增强A VS. 长安沪深300非周期A(740101) |